

S/N 10/784,476



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Alan R. Fritzberg et al.	Examiner:	Unknown
Serial No.:	10/784,476	Group Art Unit:	Unknown
Filed:	February 23, 2004	Docket:	295.044US3
Title:	HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION		

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

Pursuant to 37 C.F.R. §1.98(d), copies of most of the listed documents are not provided as these references were previously cited by or submitted to the U.S. Patent Office in connection with Applicants' prior U.S. application, Serial No. 10/159245, filed on May 29, 2002, which is relied upon for an earlier filing date under 35 U.S.C. §120. However, copies of previously uncited non-patent references are enclosed herewith.

INFORMATION DISCLOSURE STATEMENT

Serial No :10/784,476

Filing Date: February 23, 2004

Title: HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION

Page 2

Dkt: 295.044US3

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

The present application is either a U.S. national patent application filed after June 30, 2003 or an international application that entered the national stage under 35 U.S.C. § 371 after June 30, 2003. Thus, Applicant believes that the U.S. Patent & Trademark Office has waived the requirement under 37 C.F.R. 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication. The waiver is provided in a pre-OG notice from the U.S. Patent & Trademark Office entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003" and dated July 11, 2003. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).


Respectfully submitted,

ALAN R. FRITZBERG ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6903

Date 6-17-04


By 
Warren D. Woessner
Reg. No. 30,440

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 17 day of June, 2004.

CANDIS BUENDING

Name


Signature



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 1 of 14

Attorney Docket No: 295.044US3

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-20,02,017,681, 8A1	11/28/2002	Fritzberg, , et al.	424	1.11	12/11/2001
	US-20,03,011,850, 8A1	06/26/2003	Simon, , et al.	424	1.77	12/11/2002
	US-20,03,015,839, 3A1	08/21/2003	Kasina,	534	11	01/17/2003
	US-3,032,584	05/01/1962	Bergel, , et al.	260	518	03/12/1954
	US-3,032,585	05/01/1962	Bergel, , et al.	260	518	11/30/1955
	US-3,398,198	08/20/1968	Kersnar, , et al.	260	584	05/22/1967
	US-3,726,912	04/10/1973	McCrary, , et al.	260	513.N	07/02/1970
	US-3,852,414	12/03/1974	Adler, , et al.	424	1	09/13/1972
	US-3,931,396	01/06/1976	Bardy, , et al.	424	1	03/26/1974
	US-3,965,254	06/22/1976	Tofe, , et al.	424	1	11/15/1974
	US-3,974,268	08/10/1976	Subramanian, , et al.	424	1	05/30/1975
	US-3,989,730	11/02/1976	Subramanian, , et al.	260	429.7	06/11/1973
	US-4,017,596	04/12/1977	Loberg, , et al.	424	1	09/02/1975
	US-4,058,704	11/15/1977	Shimizu,	219	528	12/08/1975
	US-4,075,314	02/21/1978	Wolfangel, , et al.	424	1	04/29/1976
	US-4,104,366	08/01/1978	Schmidt-Dunker, , et al.	424	1	09/23/1976
	US-4,187,284	02/05/1980	Rolleston, , et al.	424	1	10/03/1977
	US-4,399,817	08/23/1983	Benedict,	406	20	06/30/1981
	US-4,508,625	04/02/1985	Graham,	210	695	10/06/1983
	US-4,515,767	05/07/1985	Simon, , et al.	424	1.1	06/20/1983
	US-4,560,548	12/24/1985	Simon, , et al.	424	1.1	04/10/1984
	US-4,606,907	08/19/1986	Simon, , et al.	424	1.1	07/02/1984
	US-4,639,365	01/27/1987	Sherry,	424	9	10/18/1994
	US-4,647,447	03/03/1987	Gries, , et al.	424	9	01/23/1984
	US-4,678,667	07/07/1987	Meares, , et al.	424	85	07/02/1985
	US-4,707,353	11/17/1987	Bugaj, , et al.	424	1.11	05/17/1985
	US-4,752,464	06/21/1988	Lieberman, , et al.	424	1.1	06/07/1985
	US-4,808,541	02/28/1989	Mikola, , et al.	436	501	02/20/1987
	US-4,853,209	08/01/1989	Kaplan, , et al.	424	1.1	10/27/1987
	US-4,882,142	11/21/1989	Simon, , et al.	424	1.22	12/19/1988
	US-4,885,363	12/05/1989	Tweedle, , et al.	540	465	12/23/1987
	US-4,897,254	01/30/1990	Simon, , et al.	424	1.1	03/03/1987
	US-4,897,255	01/30/1990	Fritzberg, A. R., et al.	424	1.1	06/19/1987
	US-4,898,724	02/06/1990	Simon, , et al.	424	1.1	05/14/1987

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 2 of 14

Attorney Docket No: 295.044US3

	US-4,937,333	06/26/1990	Garlich, , et al.	540	474	08/04/1989
	US-4,957,939	09/18/1990	Gries, , et al.	514	492	06/20/1986
	US-4,976,950	12/11/1990	Simon, , et al.	424	1.1	11/13/1989
	US-5,059,412	10/22/1991	Simon, , et al.	424	1.1	12/19/1988
	US-5,064,633	11/12/1991	Simon, , et al.	424	1.1	12/19/1989
	US-5,066,478	11/19/1991	Simon, , et al.	424	1.1	01/30/1990
	US-5,089,249	02/18/1992	Fritzberg, , et al.	424	1.1	06/16/1988
	US-5,202,109	04/13/1993	Fritzberg, , et al.	424	1.1	01/31/1991
	US-5,286,497	02/15/1994	Hendrickson, , et al.	424	490	05/06/1993
	US-5,300,279	04/05/1994	Simon, , et al.	424	1.77	12/19/1990
	US-5,393,512	02/28/1995	Vanderheyden, , et al.	424	1.53	09/20/1993
	US-5,587,451	12/24/1996	Athey, , et al.	528	345	10/07/1994
	US-5,621,001	04/15/1997	Canetta, , et al.	514	449	11/20/1995
	US-5,641,803	06/24/1997	Canetta, , et al.	514	449	10/18/1995
	US-5,665,761	09/09/1997	Canetta, , et al.	514	449	11/22/1996
	US-5,670,537	09/23/1997	Canetta, , et al.	514	449	09/19/1996
	US-5,679,318	10/21/1997	Vanderheyden, , et al.	424	1.11	11/21/1994
	US-5,707,610	01/13/1998	Ibsen, , et al.	424	049	05/30/1995
	US-5,708,169	01/13/1998	Hester Jr., , et al.	549	152	09/05/1996
	US-5,712,275	01/27/1998	Van Gestel,	514	222.5	01/25/1996
	US-5,714,467	02/03/1998	Boman, , et al.	514	012	03/26/1993
	US-5,714,504	02/03/1998	Lindberg, , et al.	514	338	01/23/1995
	US-5,714,604	02/03/1998	Kiefer,	540	472	05/06/1993
	US-5,756,472	05/26/1998	Liesch, , et al.	514	27	01/27/1997
	US-5,756,505	05/26/1998	Nishino, , et al.	514	253	04/01/1996
	US-5,756,685	05/26/1998	Fritzberg, , et al.	530	391.5	07/12/1996
	US-5,756,725	05/26/1998	Wilkening, , et al.	540	302	04/08/1997
	US-5,760,063	06/02/1998	Lam, , et al.	514	355	09/13/1996
	US-5,762,907	06/09/1998	Simon, J., et al.	424	1.77	10/07/1993
	US-5,770,617	06/23/1998	LaVoie, , et al.	514	394	01/21/1997
	US-5,773,421	06/30/1998	Alder, , et al.	514	025	12/21/1995
	US-5,773,443	06/30/1998	Ray, , et al.	514	256	07/18/1996
	US-5,773,696	06/30/1998	Liang, , et al.	800	205	03/29/1996
	US-5,783,570	07/21/1998	Yokota, , et al.	514	056	12/23/1996
	US-5,786,325	07/28/1998	Borromeo, , et al.	514	011	03/11/1996
	US-5,801,172	09/01/1998	Clapp-Shapiro, , et al.	514	250	07/11/1997
	US-5,807,854	09/15/1998	Bartoli, , et al.	514	248	03/21/1997
	US-5,814,634	09/29/1998	Nishino, , et al.	514	237.8	04/17/1997
	US-5,824,698	10/20/1998	Hasler, , et al.	514	394	05/14/1997
	US-5,824,874	10/20/1998	Ulbrich, , et al.	800	205	07/29/1996
	US-5,830,855	11/03/1998	Takemoto,	514	011	09/12/1996
	US-5,830,889	11/03/1998	Iwata, , et al.	514	195	02/19/1993
	US-5,837,253	11/17/1998	Cohen,	424	195.1	10/29/1996

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 3 of 14

Attorney Docket No: 295.044US3

	US-5,837,726	11/17/1998	Liu, , et al.	514	475	11/01/1995
	US-5,849,956	12/15/1998	Koga, , et al.	568	326	08/08/1997
	US-5,854,213	12/29/1998	Bouffard,	514	011	06/06/1997
	US-5,854,280	12/29/1998	Gomez, , et al.	514	456	10/18/1996
	US-5,856,347	01/05/1999	Hashiguchi, , et al.	514	390	05/23/1997
	US-5,859,032	01/12/1999	Nishino, , et al.	514	352	03/17/1997
	US-5,861,430	01/19/1999	Markonius,	514	456	06/07/1995
	US-5,863,773	01/26/1999	Gunawardana, , et al.	435	118	09/30/1997
	US-5,866,549	02/02/1999	Or, , et al.	514	029	07/03/1997
	US-5,872,249	02/16/1999	Park, , et al.	540	225	09/30/1997
	US-5,876,738	03/02/1999	Ohno, , et al.	424	404	10/24/1997
	US-5,888,526	03/30/1999	Tsubai, , et al.	424	405	04/03/1997
	US-5,888,941	03/30/1999	Bartoli, , et al.	504	262	03/31/1997
	US-5,891,890	04/06/1999	Nishino, , et al.	514	331	04/02/1998
	US-5,908,862	06/01/1999	Wai Lee, , et al.	514	546	07/31/1996
	US-5,910,498	06/08/1999	Yazaki, , et al.	514	255	07/08/1997
	US-5,917,084	06/29/1999	Jiang,	560	174	07/03/1996
	US-5,919,438	07/06/1999	Saint-Leger,	424	70.1	04/15/1997
	US-5,919,925	07/06/1999	Burton, , et al.	540	300	10/14/1997
	US-6,005,083	12/21/1999	Kasina,	534	10	03/28/1997
	US-6,177,551	01/23/2001	Kasina,	534	10	05/12/1999
	US-6,187,910	02/13/2001	Kasina,	534	10	05/12/1999
	US-6,241,961	06/05/2001	Benes, , et al.	424	1.49	03/26/1999
	US-6,528,627	03/04/2003	Kasina,	534	10	11/28/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
	CA-1078731	06/03/1980	Rolleston, , et al.	A61K	29/00	
	EP-0164843	12/18/1985	Simon, , et al.	A61K	43/00	
	EP-0210043	01/28/1987	Sadler, , et al.	A61K	49/00	
	EP-0232751	08/19/1987	Tweedle, , et al.	C07D	273/00	
	EP-0255471	02/03/1988	Gries, , et al.	C07D	257/02	
	EP-0258616	03/09/1988	Kraft, , et al.	A61K	49/00	
	EP-0287465	10/19/1988	Schaeffer, , et al.	C07D	257/02	
	EP-0374501	06/27/1990	Simon, , et al.	A61K	43/00	
	EP-0382582	08/16/1990	Parker, David , et al.	C07F	9/6524	
	EP-0408701	01/23/1991	Simon, , et al.	A61K	43/00	
	EP-0411941	02/06/1991	Garlich, , et al.	C07F	9/38	
	EP-0455380	11/06/1991	Parker, D. , et al.	A61K	49/00	
	EP-0698029	02/28/1996	Kiefer,	C07F	9/6524	
	EP-0972528	01/19/2000	Benes, , et al.	A61K	51/10	
	FR-2230374	12/20/1974	Marion, , et al.	A61K	27/04	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 4 of 14

Attorney Docket No: 295.044US3

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
	WO-0191806	12/06/2001	Wendt III, R. E., et al.	A61K	51/04	
	WO-02/062398	08/15/2002	Fritzberg, , et al.	A61K	51/04	
	WO-84/03698	09/27/1984	Mikola, , et al.	C07C	161/04	
	WO-9325240	12/23/1993	Axworthy, D. B., et al.	A61K	47/48	
	WO-94/26753	11/24/1994	Kiefer,	C07F	9/65	
	WO-95/10940	04/27/1995	Jacobson, H W., et al.	A01N	59/16	
	WO-98/43678	10/08/1998	Kasina,			

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"Bone Cancer Therapy Project Funding Awarded to Brookhaven National Laboratory for Diatide-Licensed Product", DISTRIBUTION: Business Editors and Health/Medical Writers,(1999),	
		"Breast Cancer; Genitourinary Cancer; Multiple Myeloma", <u>Annotated Guide to Cancer Chemotherapeutic Regimens 1999/2000</u> , Oncology Special Edition,13-14; 17-18; 32	
		"Chapter III: Chemotherapy Regimens in Adults", <u>In Cancer Chemotherapy Pocket Guide</u> , Robert J. Ignoffo, Editor,(1998),248-255; 338-341	
		"Multiple Myeloma", <u>In Clinical Oncology, A Multidisciplinary Approach for Physicians and Students</u> , 7th Edition, Philip Rubin, Editor,(1993),239-244	
		"NeoRx Updates Skeletal Targeted Radiotherapy (STR) Phase I/II Trial Data", <u>NeoRx Press Release</u> , (May 07, 2001),	
		"NeoRx's Multiple Myeloma Study with Targeted Radiotherapy to be Updated at ASH -- Recent Thalidomide Results Heighten Interest in New Multiple Myeloma Therapies", <u>NeoRx Press Release</u> , (November 30, 1999),	
		"NeoRx's Targeted Radiotherapy Achieves Complete Responses with Excellent Safety in Multiple Myeloma Patients", <u>NeoRx Press Release</u> , (December 7, 1999),	
		"Phase I/II Interim Data on NeoRx's STR Product in Multiple Myeloma", <u>NeoRx Press Release</u> , (1999),	
		ABRAMS, PAUL , "High-Dose Targeted Radiation to Bone and Bone Metastases", <u>CaP CURE Meeting</u> , Lake Tahoe, NV, (2000),2 pages	
		ALEXANIAN, R , et al., "Impact of Complete Remission with Intensive Therapy in Patients with Responsive Multiple Myeloma", <u>British Journal of Hematology</u> , 27(10), (2001),1037-1043	
		ANDERSON, et al., "High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients with Osteosarcoma and Bone Metastases", <u>Journal of Clinical Oncology</u> , 20, (2002),189-196	
		ANDO, A , et al., "177Lu-EDTMP: A Potential Therapeutic Bone Agent", <u>Nucl.</u>	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 5 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Med. Commun, 19(6), (1998),587-591	
		APPELBAUM, F R., et al., "Chronic and Acute Leukemias in Adults", <u>The Role of Marrow Transplantation in the Treatment of Leukemia</u> , Martinus Nijhoff Publisjers, Boston. C.D. Bloomfield, editor,(1985),229-262	
		APPELBAUM, F. R., et al., "Specific Marrow Ablation Before Marrow Transplantation Using an Aminophosphonic Acid Conjugate 166Ho-EDTMP", <u>Blood</u> , 80, (1992),1608-1613	
		BARDIES, M , et al., "Computational Methods in Radionuclide Dosimetry", <u>Physics in Medicine and Biology</u> , 41, (1996),1941-1955	
		BARLOGIE, B , et al., "Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.", <u>Blood</u> , 72(6), (December 1988),2015-2019	
		BATAILLE, R , et al., "Multiple Myeloma", <u>New England Journal of Medicine</u> , 336, (1997),1657-1664	
		BAYOUTH, J. E., et al., "Dosimetry Considerations of Bone-Seeking Radionuclides for Marrow Ablation", <u>Medical Physics</u> , 20(4), (July-August 1993),1089-1096	
		BAYOUTH, J. E., et al., "Pharmacokinetics, Dosimetry and Toxicity of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma", <u>Journal of Nuclear Medicine</u> , 36(5), (May 1995),730-737	
		BAYOUTH, J. E., et al., "Radiation Dose Distribution Within the Bone Marrow of Patients Receiving Holmium-166-Labeled-Phosphonate for Marrow Ablation", <u>Medical Physics</u> , 22(6), (June 1995),743-753	
		BEARMAN, et al., "Regimen-related Toxicity in Patients Undergoing Bone Marrow Transplantation", <u>Journal of Clinical Oncology</u> , 6(10), (October 1988),1562-1568	
		BEDDOE, A H., et al., "Measurements of Trabecular Bone Structure in Man", <u>Physics in Medicine and Biology</u> , 21(4), (July 1976),589-607	
		BENSINGER, et al., "166Ho-DOTMP and High-Dose Melphalan before Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma", Abstract P287; IXth International Workshop on Multiple Myeloma,(2003),	
		BENSINGER, B , et al., "166Holmium-DOTMP Plus Standard High Dose Chemotherapy (HDC) with Autologous Transplant Produce High Rates of Complete Remission (CR) in Multiple Myeloma (MM) Patients: An Updated Report of a Phase I/II Study", <u>Proceedings of the American Society of Clinical Oncology</u> , 20, Abstract No. 18,(2001),5a	
		BENSINGER, W , et al., "Phase I/II Study of 166Holmium-DOTMP in Combination with Melphalan +/- Total Body Irradiation (TBI) with Autologous Peripheral Blood Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>Proceedings of the American Society of Clinical Oncology 2000</u> , 19, Abstract No. 26,(2000),9a	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 6 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BENSINGER, et al., "Skeletal Targeted Radiotherapy (STR) with 166Ho-DOTMP plus Melphalan and Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma(MM)", <u>Meeting Proceedings of ASCO, 22</u> , ASCO Annual Meeting, May 2003; Abstract Number 3346,(2003),833	
		BIGLER, R , et al., "Skeletal Distribution of Mineralized Bone Tissue in Humans", <u>Health Physics, 31</u> , (1976),213-218	
		BOUSSIOTIS, V A., et al., "Bone Marrow Transplantation for Low-grade Lymphoma and Chronic Lymphocytic Leukemia", <u>Semin Hematol, 36</u> , (1999),209-216	
		BREITZ, H , "Dosimetry in a Myeloablative Setting", Annual Society of Nuclear Medicine Meeting, Continuing Education Course,(2001),	
		BREITZ, H , et al., "Dosimetry in Myeloblative Setting", <u>Cancer Biother. Radiopharm., 17(1)</u> , (2002),119-128	
		BREITZ, et al., "Dosimetry of High Dose Skeletal Targeted Radiotherapy (STR) with 166-Ho-DOTMP", <u>Cancer Biotherapy and Radiopharmaceuticals, 18</u> , (2003),225-230	
		BREITZ, H , et al., "Dosimetry of High Dose Skeletal Targeted Radiotherapy wit Ho-166 DOTMP", <u>Presentation at VIIth International Radiopharmaceutical Dosimetry Symposium, (2002)</u> ,	
		BREITZ, H , et al., "Multiple Myeloma: Skeletal Targeted Radiotherapy with 166-Ho-DOTMP for Treatment of Multiple Myeloma", <u>Presented at "Targeted Radionuclide Therapy"</u> , (2002),	
		BREITZ, H , "Quantitative Dosimetry Workup in a Myeloablative Setting", Presentation at the 48th Annual Society for Nuclear Medicine Meeting,(2001),	
		CHAMPLIN, R , et al., "166Holmium-DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen for Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM)", <u>Blood, 94(10)</u> , American Society of Hematology, Abstract No. 3133,(1999),709a	
		CHAMPLIN, R , et al., "Bone Marrow Transplantation for Acute Leukemia: Recent Advances and Comparison with Alternative Therapies", <u>Seminars in Hematology, 24</u> , (1987),55-67	
		CHAMPLIN, R. , et al., "Holmium-166 DOTMP, A Bone Seeking Radiochelate for Selective Marrow Radiotherapy with Bone Marrow Transplantation (BMT) for Multiple Myeloma", <u>Experimental Hematology, 21</u> , Abstracts, 22nd Annual Meeting of the International Society for Experimental Hematology, Rotterdam, The Netherlands, Abstract No. 393,(1993),1117	
		CHAMPLIN, R. , et al., "Holmium-166 DOTMP, A Bone Seeking Radiochelate For Selective Marrow Radiotherapy with Bone Marrow Transplantation (BMT) for Multiple Myeloma", <u>Blood, 82</u> , Abstracts, American Society of Hematology Thirty-Fifth Annual Meeting, St. Louis, MO, Abstract No. 1051,(1993),266a	
		CHAMPLIN, R , et al., "Phase I/II Study of Targeted Radiotherapy Using 166Ho-	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 7 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DOTMP with Melphalan and Peripheral Blood Stem Cell Transplant for Multiple Myeloma", A slide presentation, International Society of Experimental Hematology,(2000),	
		CHAMPLIN, R , et al., "Role of Bone Marrow Transplantation in the Treatment of Hematologic Malignancies and Solid Tumors: Critical Review of Syngeneic, Autologous, and Allogeneic Transplants.", <u>Cancer Treatment Reports</u> , <u>68</u> , (1984),145-161	
		CHAMPLIN, R. , et al., "Two Phase I/II Studies of 166Holmium-DOTMP in Combination with Melphalan With or Without Total Body Irradiation as a Preparative Regimen for Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>Experimental Hematology</u> , <u>27(7)</u> , Abstract No. 196, Program and Abstracts, 28th Annual Meeting of the International Society for Experimental Hematology, Monte Carlo, Monaco.,(1999),88	
		CLEYNHENS, et al., "99mTc-EC-AMDP, a Bone Agent with Rapid Clearance from Soft Tissue", <u>Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine</u> , <u>5</u> , (1999),605-609	
		COHEN, et al., "Bisphosphonates and Tetracycline: Experimental Models for Their Evaluation in Calcium-Related Disorders", <u>Pharmaceutical Research</u> , <u>15</u> , (1998),606-613	
		CUNNINGHAM, D , et al., "High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data", <u>Journal of Clinical Oncology</u> , <u>12</u> , (1994),764-768	
		DISPENZIERI, et al., "A Phase I Study of a Conditioning Regimen for Peripheral Stem Cell Transplantation (PBSCT) for Multiple Myeloma (MM): 153Samarium Ethylenediaminetetramethylenephosphonate (153SM-EDMPT) and Melphalan", <u>Blood</u> , <u>96</u> , Abstract 2397,(2000),558a	
		DISPENZIERI, et al., "A Phase I/II Dose Escalation Study of 153-Samarium EDTMP (153-Sm-EDMTP) with Fixed Dose Melphalan Peripheral Stem Cell Transplantation (PBSCT) for Multiple Myeloma (MM)", <u>Blood</u> , <u>98</u> , Abstract 2855,(2001),682a-683a	
		DURRANT, SIMON , et al., "Sm-153 Lexitronam, Limb Irradiation and Stem Cell Transplantation for the Treatment of Multiple Myeloma", Amer. Soc. Hemeotology Annual Meeting, Orlando, FL.,(2001),	
		EARY, JANET F., et al., "Samarium-153-EDTMP Biodistribution and Dosimetry Estimation", <u>The Journal of Nuclear Medicine</u> , <u>34</u> , (1993),1031-1036	
		ECKERMAN, K , et al., "Dose Conversion Factors for Marrow and Bone by Skeletal Regions", <u>Journal of Nucler Medicine</u> , <u>35</u> , (1994),112P	
		EISENHUT, M , "Iodine-131-Labeled Diphosphonates for the Palliative Treatment of Bone Metastases: I. Organ Distribution and Kinetics of I-131 BDP3 in Rats", <u>The Journal of Nuclear Medicine</u> , <u>25</u> , (1984),1356-1361	
		EISENHUT, et al., "The Influence of Substituents in 99mTc-Benzylidenediphosphonate Complexes on their Organ Distribution in Rats",	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 8 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Nuklearmedizin, 23, (1984),119-122	
		FIRUSIAN, N , et al., "Results of 89Strontium Therapy in Patients with Carcinoma of the Prostate and Incurable Pain from Bone Metastases: A Preliminary Report", <u>The Journal of Urology</u> , 116, (1976),764-768	
		FRITZBERG, ALAN R., "Holmium-166 DOTMP for Marrow Ablation: Clinical Studies to Demonstrate Efficacy in Multiple Myeloma", Society of Nuclear Medicine Annual Meeting, St. Louis,(2000),	
		FUJISAKI, et al., "Physicochemical Characterization of Bisphosphonic Carboxyfluorescein for Osteotropic Drug Delivery", <u>J Pharm Pharmacol.</u> , 48, (1996),798-800	
		GARLICH, J R., et al., "Chemical Considerations of 153Sm-EDTMP, a New Therapeutic Bone Agent", Sixth International Symposium on Radiopharmaceutical Chemistry: Abstracts. Boston, June 29-July 3, 1986. Paper 140,(1986),317-319	
		GARLICH, J. R., et al., "Chemistry of Novel Macrocyclic Aminophosphonic Acid Chelates of Rare Earth Radionuclides and Their in vivo Biodistribution", <u>The Journal of Nuclear Medicine</u> , 34, Abstract Book, Proceedings of the 40th Annual Meeting, Toronto, Ontario, Canada, Abstract No. 1134,(1993),244P	
		GERALDES, C F., et al., "Synthesis, Protonation Sequence, and NMR Studies of Polyazamacrocyclic Methylene phosphonates", <u>Inorganic Chemistry</u> , 28, (1989),3336-3341	
		GIRALT, et al., "166Ho-DOTMP Plus Melphalan Followed by Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma: Results of Two Phase I/II Trials", <u>Blood</u> , Blood First Edition Paper; DOI 10.1182/2002-10-3250,(2003),1-38	
		GIRALT, S , et al., "Hemorrhagic Cystitis after Targeted Radiotherapy with Holmium-DOTMP (166HO) for Multiple Myeloma (MM) is Preventable with Bladder Irrigation", <u>Blood</u> , 96(11), Abstract No. 1686,(2000),	
		GIRALT, et al., "Long-Term Follow-Up of 83 Patients with Multiple Myeloma (MM) Treated on a Phase I-II Study of Skeletal Targeted Radiotherapy (STR) Using 166Ho-DOTMP Plus Melphalan with or without Total Body Irradiation (TBI) and Autologous Hematopoietic Stem Cell ...", <u>Blood</u> , 100, 44th Annual Meeting of the American Society of Hematology; Abstract 670,(2002),179a	
		GIRALT, S , et al., "Preliminary Results of a Phase I/II Study of Multiple Myeloma (MM) Patients Treated with 166Holmium-DOTMP in Combination with High Dose Melphalan +/- Total Body Irradiation (TBI) with Autologous Stem Cell Transplant (ASCT)", <u>Blood</u> , 96(11), Abstract No. 2395,(2000),	
		GIRALT, S , et al., "Results of a Phase I/II Trial with 166Ho-DOTMP Plus High Dose Chemotherapy in Patients with Multiple Myeloma", <u>VIIIth Int'l Multiple Myeloma Proceedings</u> , Abstract No. S24,(2001),40-41	
		GIRALT, S , et al., "Two Phase I/II Studies of 166Holmium-DOTMP in	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 9 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Combination with or without TBI as a Preparative Regimen for Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>VIIth Int'l Multiple Myeloma Workshop</u> , Abstract No. 033, Meeting Held September 1-5, 1999,(1999),117	
		GOECKELER, W F., et al., "Samarium-153 Radiotherapeutic Bone Agents", <u>Nucl. Med. Biol.</u> , 13, (1986),479-482	
		HASSFJELL, S. P., et al., "212Bi-DOTMP: An Alpha Particle Emitting Bone-Seeking Agent for Targeted Radiotherapy", <u>Nuclear Medicine and Biology</u> , 24, (1997),231-237	
		HOGAN, et al., "Successful Treatment of POEMS Syndrome with Autologous Hematopoietic Progenitor Cell Transplantation", <u>Bone Marrow Transplantation</u> , 28, (2001),305-309	
		HSIA, C , et al., "Preparation of 113mIn-DTPMP Bone Scanning Agent and its Preliminary Clinical Application", <u>Chemical Abstracts</u> , 95, (1981),305	
		JARVIS, et al., "Characterization of the Bisphosphonate Recognition Site on Hydroxyapatite Using Radioligand Binding Techniques with [14C]Citric Acid", <u>Calcif Tissue Int.</u> , 52, (1993),372-377	
		JOHN, E K., et al., "Formulation Development and Stability of the 166Ho-DOTMP for High Level Dosages - A Skeletal Targeted Radiotherapeutic", <u>Journal of Nuclear Medicine</u> , 42, Proceedings of the SNM 48th Annual Meeting, No. 1122,(2001),267P	
		KABACHNIK, I M., et al., "Synthesis and Acid-Base and Complex-Forming Properties of 1,4,7,10 - Tetrakis (dihydroxyphosphorylmethyl) - 1,4,7,10 - tetraazacyclododecane", <u>Bulletin of the Academy of Sciences of the USSR: Division of Chemical Science</u> , 33, (1984),777-782	
		KABACHNIK, M I., et al., "Synthesis and Study of a New Complexone - N,N',N" - Tris-(Dihydroxyphosphorylmethyl) - 1,4,7 - Triazacyclononane", <u>Bulletin of the Academy of Sciences of the USSR: Division of Chemical Science</u> , 33, (1984),769-777	
		KAPLAN, E , et al., "Therapy of Carcinoma of the Prostate Metastatic to Bone with P32 Labeled Condensed Phosphate", <u>The Journal of Nuclear Medicine</u> , 1, (1960),1-13	
		KASI, L. P., et al., "Ho-166DOTMP: A New Agent for Bone Marrow Ablation", <u>The Journal of Nuclear Medicine</u> , 34, Abstract Book, Proceedings of the 40th Annual Meeting, Toronto, Ontario, Canada, Abstract No. 125,(1993),33P	
		KEELING, A. A., et al., "Yttrium-90-EDTMP: A Radiotherapeutic Agent in the Treatment of Leukaemias", <u>British Journal of Cancer</u> , 60, (1989),74-78	
		KETRING, A R., "153Sm-EDTMP and 186Re-HEDP as Bone Therapeutic Radiopharmaceuticals", <u>Nucl. Med. Biol.</u> , 14(3), (1987),223-232	
		KOHN, D B., "The Current Status of Gene Therapy Using Hematopoietic Stem Cells", <u>Currunt Opinion in Pediatr.</u> , 7, (1995),56-63	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 10 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KOTHARI, K K., et al., "186RE and 188RE Phosphonate Ligands", <u>The Journal of Nuclear Medicine</u> , 40, Proceedings of the 46th Annual Meeting, Abstract No. 1015,(1999),228P	
		KRISHNAMURTHY, G T., et al., "Tin-117m(4+)DTPA: Pharmacokinetics and Imaging Characteristics in Patients with Metastatic Bone Pain", <u>The Journal of Nuclear Medicine</u> , 38, (1997),230-237	
		KRIVIT, W , et al., "Bone Marrow Transplantation as Effective Treatment of Central Nervous System Disease in Globoid Cell Leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and ...", <u>Curr Opin Neurol</u> , 12(2), (1999),167-176	
		LARSEN, et al., "Preliminary Evaluation of a New Radiolabelled Bisphosphonate", <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , XLI, (1998),823-830	
		LOGAN, K W., et al., "Radiation Dose Calculations in Persons Receiving Injection of Samarium-153-EDTMP", <u>J. Nucl. Med.</u> , 28, (1987),505-509	
		MA, J , et al., "Indium-113m Labeled Bone Imaging Agents - Animal Experiment and Clinical Application of 113mIn-DTPMP and 113mIn-EDTMP", <u>Chemical Abstracts</u> , 93, (1980),285	
		MATHIEU, L. , et al., "Preparation of Rhenium-186 Labelled EHDP and its Possible Use in the Treatment of Osseous Neoplasms", <u>International Journal of Applied Radiation and Isotopes</u> , 30, (1979),725-727	
		MCCULLOUGH, S P., et al., "99mTc-MDP as a Surrogate Quantitative Imaging Agent for High Dose 166Ho-DOTMP Bone Marrow Ablation Therapy", <u>Society of Nuclear Medicine Proceedings of the 47th Annual Meeting</u> , 41(5), (2000),147P	
		MCCULLOUGH, S. P., et al., "Non-target Organ Doses in Patients Undergoing Bone Marrow Ablation with Ho-166-DOTMP", <u>The Journal of Nuclear Medicine</u> , 39, No. 5, Abstract Book, Scientific Abstracts of the 45th Annual Meeting of the Society of Nuclear Medicine, Toronto, Ontario, Canada, Abstract No. 838,(1998),186P	
		MCCULLOUGH, S P., et al., "Pharmacokinetics and Patient Specific Dosimetry of High Dose 166Ho-DOTMP Therapy Used for Treatment of Breast Cancer Metastatic to Bone", <u>The Journal of Nuclear Medicine: Proceedings of the 46th Annual Meeting</u> , 40, (1999),40P	
		MCCULLOUGH, S P., et al., "Preliminary Correlation of Bone Marrow Dose Distributions and Disease Response in Multiple Myeloma Patients Treated with Target Skeletal Radiotherapy", <u>The Journal of Nuclear Medicine, Proceedings of the 47th Annual Meeting</u> , 41(5), Abstract No. 327,(2000),83P	
		MOREAU, P , et al., "Melphalan 220 mg/m2 Followed by Peripheral Blood Stem Cell Transplantation in 27 Patients with Advanced Multiple Myeloma", <u>Bone Marrow Transplant</u> , 23(10), (1999),1003-1006	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 11 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NAIL, S L., "The Relationship Between the Structure of Aluminum Hydride Gel and Acid Reactivity", <u>Chemical Abstracts</u> , 84, (1976),353	
		O'MARA, R E., et al., "Rare Earth Nuclides as Potential Agents for Skeletal Imaging", <u>The Journal of Nuclear Medicine</u> , 10, (1969),49-51	
		PARKS, N. J., et al., "Bone Marrow Transplantation in Dogs After Radio-Ablation with a New Ho-166 Amino Phosphonic Acid Bone-Seeking Agent (DOTMP)", <u>Blood</u> , 82 (1), (1993),318-325	
		PAULSON, TOM , "Seattle Leads in Stem Cell Study: Fred Hutchinson Team Explores Options with Autoimmune Project", <u>The Seattle Post-Intelligencer</u> , (1999),	
		PODOLOFF, D A., et al., "Phase I/II Studies of Holmium-166 DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen For Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma (MM)", <u>European Journal of Nuclear Medicine</u> , 26(9), Abstract No. PS-641,(1999),1213	
		PODOLOFF, D. A., et al., "Phase I/II Study of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma Prior to Bone Marrow Transplantation (BMT)", <u>The Journal of Nuclear Medicine</u> , 35, Abstract Book, Proceedings of the 41st Annual Meeting, Orlando, FL, Abstract No. 139,(1994),37P	
		PODOLOFF, DONALD A., "The Role of Radioisotopes and the Treatment of Solid Tumors", <u>Accomplishments with Medical Isotopes: Advanced Health Care for the 21st Century</u> , Medical Isotopes and the 21st Century,(1999),	
		PODOLOFF, D. A., et al., "Update on the Ho-166 DOTMP Bone Marrow Ablation Trial at U.T.M.D. Anderson Cancer Center", <u>Journal of Nuclear Medicine</u> , 37, Supplement: Radiolabeled IUdr, Abstract No.1053,(1996),234P	
		RAJENDRAN, J G., et al., "High Dose Holmium-166 DOTMP Myeloablative Treatment for Multiple Myeloma", <u>Journal of Nuclear Medicine</u> , Proceedings of the 47th Annual Meeting,(2000),146P	
		RAJENDRAN, et al., "High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation", <u>J Nucl Med</u> , 43, (2002),1383-1390	
		RAJENDRAN, J G., et al., "Holmium-166 DOTMP: An Agent with Ideal Physical and Pharmacokinetic Characteristics for Use in Myeloablative Treatment of Multiple Myeloma", <u>Western Regional Soc. Nucl. Med.</u> , (2000),	
		ROSCH, F. , et al., "Radiation Doses of Yttrium-90 Citrate and Yttrium-90 EDTMP as Determined via Analogous Yttrium-86 Complexes and Positron Emission Tomography", <u>European Journal of Nuclear Medicine</u> , 23, (1996),958-966	
		ROSOFF, B , et al., "Distribution and Excretion of Radioactive Rare-Earth Compounds in Mice", <u>International Journal of Applied Radiation and Isotopes</u> , 14, (1962),129-135	

EXAMINER

DATE CONSIDERED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 12 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SALTUS, RICHARD, "Double Transplant's Success May Lead to End of Rejection Drugs", <u>The Seattle Post-Intelligencer</u> , (1999),	
		SCHMIDT, C G., et al., "89-Sr for the Treatment of Incurable Pain in Patient with Neoplastic Osseous Infiltrations", <u>Int. J. Clin. Pharmacol.</u> , 9, (1974),199-205	
		SHERRY, A D., "31P and 23Na NMR Lanthanide Induced Shifts in Axially Symmetric Macrocyclic Phosphonate Complexes", <u>Inorganica Chimica Acta</u> , 139, (1987),137-139	
		SHERRY, A D., et al., "Dy(DOTP)5-: A New, Stable, 23Na Shift Reagent", <u>Journal of Magnetic Resonance</u> , 76, (1988),528-533	
		SHIBATA, Y., et al., "Selectively Eliminated Blood Monocytes and Splenic Suppressor Macrophages in Mice Depleted of Bone Marrow by Strontium 89", <u>J. Leukocyte Biol.</u> , 38, (1985),659-669	
		SIMON, J., et al., "153Sm-EDTMP, a Potential Therapeutic Bone Agent", Sixth International Symposium on Radiopharmaceutical Chemistry: Abstracts. Boston, June 29-July 3, 1986. Paper 141,(1986),320-322	
		SPIERS, F W., et al., "Mean Skeletal Dose Factors for Beta-particle Emitters in Human Bone. Part II: Surface-seeking Radionuclides", <u>British Journal of Radiology</u> , 54, (1981),500-504	
		SRIVASTAVA, S C., et al., "10Ruthenium-97 Labeled Compounds - A New Class of Radiopharmaceuticals", <u>Medical Department, Brookhaven National Laboratory, Upton, NY 11973</u> , 123-133	
		STABIN, M G., et al., "Bremsstrahlung Radiation Dose in Yttrium-90 Therapy Applications", <u>J Nucl Med</u> , 35, (1994),1377-1380	
		SUBRAMANIAN, G., et al., "Indium-113m Labeled Polyfunctional Phosphonates as Bone Imaging Agents", <u>Chemical Abstracts</u> , 87, (1977),243	
		SUBRAMANIAN, G., et al., "Indium-113m-Labeled Polyfunctional Phosphonates as Bone-Imaging Agents", <u>Journal of Nuclear Medicine</u> , 16, (1975),1080-1084	
		SUBRAMANIAN, G., et al., "Localization of new Tc-99m Labeled Diphosphonates in Experimental Bone Lesions", Presented at the 19th International Annual Meeting of the Society of Nuclear Medicine Europe, Bern, Switzerland, September 8-11, 1981,(1981),	
		SWAILEM, FAYEZ, et al., "In vivo Tissue Uptake and Retention of Sn-117m(4+)DTPA in a Human Subject with Metastatic Bone Pain and in Normal Mice", <u>Nuclear Medicine & Biology</u> , 25, (1988),279-287	
		TANANAEV, I V., et al., "Lanthanide Ethylenediametetramethylphosphonates", <u>Chemical Abstracts</u> , 96, (1982),553	
		THOMAS, S R., et al., <u>Journal of Nuclear Medicine</u> , 35, (1994),73	
		THOMAS, E D., "Clinical Trials with Bone Marrow Transplantation", <u>Clinical Trials in Cancer Medicine</u> , Academic Press, Inc.,(1985),239-253	
		THOMAS, E D., "Marrow Transplantation for Malignant Diseases", <u>Journal of Clinical Oncology</u> , 1, (1983),517-531	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 13 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		THOMAS, E D., et al., "Marrow Transplantation for Thalassemia", <u>Annals New York Academy of Sciences</u> , 445, (1985),417-427	
		THOMAS, S R., "MIRD Pamphlet No. 14: A Dynamic Urinary Bladder Model for Radiation Dose Calculations.", <u>Journal of Nuclear Medicine</u> , 33, Published erratum appears in <u>Journal of Nuclear Medicine</u> , 35, 73 (1994), (1992),783-802	
		TURNER, J H., et al., "Radiopharmaceutical Therapy of 5T33 Murine Myeloma by Sequential Treatment with Samarium-153 Ethylenediaminetetramethylene Phosphonate, Melphalan, and Bone Marrow Transplantation", <u>Journal of the National Cancer Institute</u> , 85(18), (1993),1508-1513	
		TURNER, J. H., et al., "Samarium - 153 EDTMP Therapy of Disseminated Skeletal Metastasis", <u>Eur J. Nucl Med</u> , 15, (1989),784-795	
		TURNER, J. H., et al., "Samarium-153 EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation in the C57BL/KalwRij mouse as a model for treatment of multiple myeloma", <u>Australian & New Zealand J of Medicine</u> , 22, (1992),405	
		TURNER, J. H., et al., "Samarium-153 EDTMP and melphalan chemoradiotherapy regimen for bonemarrow ablation prior to marrow transplantation: an experimental model in the rat", <u>Nuclear Medicine Communications</u> , 13(5), (1992),321-329	
		VOLKERT, W A., et al., "Characteristics of Tc-99m-Complexes of Large Tetraphosphonates", 1984 Abstract Form for Scientific Exhibits Society of Nuclear Medicine 31st Annual Meeting, Los Angeles, California, June 5-8, 1984.,	
		WEININGER, J , "Re-186 HEDP: A Potential Therapeutic Bone Agent", 24(5), <u>Proceedings of the 30th Annual Meeting - Posters</u> ,P125	
		WENDT, R E., "An Improved Estimate of Activity in Skull-Like Structures", <u>Journal of Nuclear Medicine</u> , 42, <u>Proceedings of the 48th Annual Meeting</u> ,(2001),193P	
		WENDT, R E., et al., "Correction of Scatter and Septal Penetration in Ho-166 Images to Enable Narrow Beam Attenuation Correction", <u>Journal of Nuclear medicine</u> , 43(5),(2002),221P-222P	
		WINSTON, M A., "Radioisotope Therapy in Bone and Joint Disease", <u>Seminars in Nuclear Medicine</u> , 9, (1979),114-120	
		WISEMAN, et al., "Bone Targeted Radioisotope Therapy for Treatment of Multiple Myeloma and Bone Tumors", <u>International Journal of Cancer</u> , 13, Abstract O 109,(2002),104	
		WISEMAN, et al., "Residual Whole Body 153Samarium Activity Predicts for Successful Autologous Peripheral Blood Progenitor Cell (PBPC) Engraftment Following High Dose 153Samarium Ethylene Diamine Tetramethylene Phosphonate (153Sm-EDTMP) Targeted Radiotherapy", <u>Blood</u> , 96, Abstract 1811,(2000),421	
		YOUNG, J C., et al., "High Dose Samarium-153 Ethylenediaminetetramethylene	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/784,476
Filing Date	February 23, 2004
First Named Inventor	Fritzberg, Alan
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 14 of 14

Attorney Docket No: 295.044US3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Phosphate (SM-153 EDTMP) in the Treatment of Bone Sarcomas", <u>The Journal of Nuclear Medicine</u> , 40(5), Proceedings of the 46th Annual Meeting, (1999), 219P	
		ZEEVAART, JAN R., et al., "Metal-ion Speciation in Blood Plasma Incorporating the Bisphosphonate, 1-hydroxy-4-aminopropylidenediphosphonate (APD), in Therapeutic Radiopharmaceuticals", <u>Journal of Inorganic Biochemistry</u> , 73, (1999), 265-272	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached